FILE:CELG/CELG-8K-20090427085148.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
o
o
o
 
 
 
ITEM 8.01 OTHER EVENTS
On April 27, 2009, Celgene Corporation announced that the company's Board of Directors has authorized the repurchase of up to $500 million of the Company's common stock through April 2011.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1  Press Release dated April 27, 2009
This exhibit is furnished pursuant to Item 8.01 and shall not be deemed to be "filed."
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CELGENE CORPORATION
Date: April 27, 2009
By: Name: David W. Gryska Title: Senior Vice President and Chief Financial Officer
s/ David W. Gryska                                       
/

Exhibit 99.1
Celgene Corporation (NASDAQ: CELG) today announced that the company's Board of Directors has authorized the repurchase of up to $500 million of the Company's common stock through April 2011.
SUMMIT, NJ  (April 27, 2009) 
Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene's management and in accordance with the requirements of the Securities and Exchange Commission. As of December 31, 2008, Celgene had 459,129,629 shares of common stock outstanding.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's Web site at www.celgene.com.
About Celgene
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as
Form 10-K
, 10-Q and 8-K reports.


